Evidence map›Paper›PMID 30043530›Full record

ArticleGlia2018

Astroglia contribute to the pathogenesis of spinocerebellar ataxia Type 1 (SCA1) in a biphasic, stage-of-disease specific manner.

Joo Hyun Kim, Abigail Lukowicz, Wenhui Qu, Andrea Johnson, Marija Cvetanovic

Open access · greenAbstract read
In one paragraph

Article in Glia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  17. Article
  18. Differential effects of Wnt-β-catenin signaling in Purkinje cells and Bergmann glia in spinocerebellar ataxia type 1.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joo Hyun KimDepartment of Neuroscience, Institute for Translational Neuroscience, University of Minnesota 2101 6th Street SE, Minneapolis, Minnesota.
Abigail LukowiczDepartment of Neuroscience, Institute for Translational Neuroscience, University of Minnesota 2101 6th Street SE, Minneapolis, Minnesota.
Wenhui QuDepartment of Neuroscience, Institute for Translational Neuroscience, University of Minnesota 2101 6th Street SE, Minneapolis, Minnesota.
Andrea JohnsonDepartment of Neuroscience, Institute for Translational Neuroscience, University of Minnesota 2101 6th Street SE, Minneapolis, Minnesota.
Marija CvetanovicDepartment of Neuroscience, Institute for Translational Neuroscience, University of Minnesota 2101 6th Street SE, Minneapolis, Minnesota.ORCID 0000-0001-7744-736X
University of Minnesota · US

Funding

Understanding cellular and molecular mechanisms of neurodegenerationR01NS107387 · NINDS · UNIVERSITY OF MINNESOTA · PI CVETANOVIC, MARIJA · 2018 to 2021
$1.3M
National Ataxia FoundationNINDS NIH HHS R01 NS107387Wallin Foundation
6 · The paper itself

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a fatal, dominantly inherited neurodegenerative disease caused by the expansion of CAG repeats in the Ataxin-1 (ATXN1) gene. SCA1 is characterized by balance and coordination deficits due to the predominant loss of Purkinje neurons in the cerebellum. We previously demonstrated that cerebellar astrogliosis beings during the early stages of SCA1, prior to onset of motor deficits and loss of Purkinje neurons. We communicate here that cerebellar astrogliosis contributes to SCA1 pathogenesis in a biphasic, stage of disease dependent manner. We modulated astrogliosis by selectively reducing pro-inflammatory transcriptional regulator nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling in astroglia via a Cre-lox mouse genetic approach. Our results indicate that inhibition of astroglial NF-κB signaling, prior to motor deficit onset, exacerbates disease severity. This is suggestive of a neuroprotective role mediated by astroglia during early stage SCA1. In contrast, inhibition of astroglial NF-κB signaling during late stage of disease ameliorated motor deficits, indicating a potentially harmful role of astroglia late in SCA1. These results indicate that astrogliosis may have a critical and dual role in disease. If so, our results imply that anti-inflammatory astroglia-based therapeutic approaches may need to consider disease progression to achieve therapeutic efficacy.

Indexed as

AnimalsAstrocytesAtaxin-1CerebellumDisease Models, AnimalDisease ProgressionFemaleGlial Fibrillary Acidic ProteinGliosisI-kappa B KinaseMaleMice, Inbred C57BLMice, TransgenicMicrogliaMotor ActivityNeuronsAtaxin-1Glial Fibrillary Acidic Proteinglial fibrillary astrocytic protein, mouseI-kappa B KinaseNF-kappa BastrogliaATAXIN-1cerebellumneurodegenerationneurodestructiveneuroprotectivenuclear factor kappa b

Identifiers

PMID30043530
PMCPMC8049102
OpenAlexW2884639577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.